头颈部鳞状细胞癌免疫微环境及其作用机制的 最新研究进展及展望. (Chinese)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Alternate Title:
      Recent advances and prospect in immune microenvironment and its mechanisms of function in head and neck squamous cell carcinoma. (English)
    • Abstract:
      Head and neck cancer (HNC) remains a significant cause of morbidity and mortality. The most prevalent pathology among HNC is head and neck squamous cell carcinoma (HNSCC). The tumor microenvironment (TME) encompasses the components surrounding tumor cells, including immune cells, stromal cells, extracellular matrix (ECM), blood and lymph vessels. Strategies targeting the TME have yielded significant outcomes. Thus, further exploration of the interactions between TME components is crucial. This review discussed recent advances in cytotoxic T lymphocytes (CTL), CD4+ T lymphocytes, regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC), natural killer (NK) cells and tumor-associated macrophages (TAM) in HNSCC TME. The article summarized herein primarily focused on restoring the activity of anti-tumor cells and eliminating the immunosuppressive effects of Treg and so on, to provide new insights for more effective HNSCC therapy. [ABSTRACT FROM AUTHOR]
    • Abstract:
      头颈部恶性肿瘤(head and neck cancer,HNC)作为一类常见的恶性肿瘤,至今仍有较高的发病率和死亡率。 在HNC中,头颈部鳞状细胞癌(head and neck squamous-cell carcinoma,HNSCC)是最常见的病理学类型。肿瘤微环境 (tumor microenvironment,TME)是指肿瘤细胞周围的成分,主要包括免疫细胞、基质细胞、细胞外基质(extracellular matrix,ECM)、血管和淋巴管及其驱动分子。一些针对TME的肿瘤治疗策略已在临床上广泛应用,并产生了显著的治 疗效果。更深层次地探索TME中各组分之间的相互作用机制具有重要意义。本文综述了HNSCC的TME中细胞毒性T淋巴 细胞(cytotoxicity T lymphocyte,CTL)、CD4+ T 淋巴细胞、调节性T细胞(regulatory T cell,Treg)、髓样来源抑制细 胞(marrow-derived myeloid cell,MDSC)、自然杀伤(natural killer,NK)细胞、肿瘤相关巨噬细胞(tumor-associated macrophage,TAM)的最新研究进展。本文中总结的研究主要聚焦于如何恢复抗肿瘤细胞活性,以及如何消除Treg等免疫 抑制细胞的免疫抑制作用,旨在为研究更有效的HNSCC治疗方法提供新思路。. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of China Oncology is the property of Editorial Board of China Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)